• Media type: E-Article
  • Title: A bifunctional colchicinoid that binds to the androgen receptor
  • Contributor: Sharifi, Nima; Hamel, Ernest; Lill, Markus A.; Risbood, Prabhakar; Kane, Charles T.; Hossain, Md Tafazzal; Jones, Amanda; Dalton, James T.; Farrar, William L.
  • imprint: American Association for Cancer Research (AACR), 2007
  • Published in: Molecular Cancer Therapeutics
  • Language: English
  • DOI: 10.1158/1535-7163.mct-07-0163
  • ISSN: 1535-7163; 1538-8514
  • Keywords: Cancer Research ; Oncology
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title> <jats:p>Castrate-resistant prostate cancer (CRPC) continues to be dependent on the androgen receptor (AR) for disease progression. We have synthesized and evaluated a novel compound that is a conjugate of colchicine and an AR antagonist (cyanonilutamide) designed to inhibit AR function in CRPC. A problem in multifunctional AR-binding compounds is steric hindrance of binding to the embedded hydrophobic AR ligand-binding pocket. Despite the bulky side chain projecting off of the AR-binding moiety, this novel conjugate of colchicine and cyanonilutamide binds to AR with a Ki of 449 nmol/L. Structural modeling of this compound in the AR ligand-binding domain using a combination of rational docking, molecular dynamics, and steered molecular dynamics simulations reveals a basis for how this compound, which has a rigid alkyne linker, is able to bind to AR. Surprisingly, we found that this compound also binds to tubulin and inhibits tubulin function to a greater degree than colchicine itself. The tubulin-inhibiting activity of this compound increases cytoplasmic AR levels in prostate cancer cells. Finally, we found that this compound has greater toxicity against androgen-independent prostate cancer cells than the combination of colchicine and nilutamide. Together, these data point to several ways of inhibiting AR function in CRPC. [Mol Cancer Ther 2007;6(8):2328–36]</jats:p>
  • Access State: Open Access